Dual-Target Insight into Drug Discovery from Natural Products as Modulators of GLP-1 and the TXNIP–Thioredoxin Antioxidant System in Metabolic Syndrome

Metabolic Syndrome (MetS), a cluster of interconnected metabolic abnormalities, poses a growing global health burden. A well-established therapeutic target for the diseases is the incretin hormone glucagon-like peptide-1 (GLP-1); however, synthetic agonists have drawbacks such as expense, injectable administration, and side effects. Concurrently, one of the main pathogenic characteristics of MetS is oxidative stress, in which the Thioredoxin-Interacting Protein (TXNIP)/thioredoxin system is a critical player. The strong evidence that natural compounds derived from plant, marine, and microbiological sources can simultaneously target the TXNIP–thioredoxin antioxidant axis and GLP-1 signaling is examined in this study. These substances can limit TXNIP expression and increase thioredoxin activity while also stimulating GLP-1 secretion, inhibiting dipeptidyl peptidase-4 (DPP-4), or acting as GLP-1 receptor agonists. A cycle of reinforcement is created by these two actions: Pancreatic β-cell activity and incretin responsiveness are improved by GLP-1-mediated TXNIP downregulation, which also strengthens antioxidant defense. However, translational development must overcome major pharmacological obstacles, especially those related to bioavailability, metabolic stability, and standardization, despite encouraging preclinical effectiveness. To speed up this translational process, integrative computational techniques (such as molecular docking, network pharmacology, and artificial intelligence) are strong tools for lead optimization and creation of hypothesis. Thus, natural products can provide a special chance to discover multi-target treatments that comprehensively address the oxidative and hormonal causes of MetS.

• Publication year

  2025

• Venue

  Antioxidants

• Publication date

  2025-11-01

• Fields of study

  Medicine, Chemistry

• Identifiers
  DOI 10.3390/antiox14111364PMID 41300521PMCID 12649192
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Strategies to Enhance the Therapeutic Efficacy of GLP‐1 Receptor Agonists through Structural Modification and Carrier Delivery

  2025cited by this paper
• TXNIP promotes viral replication by disrupting MAVS-mediated antiviral signaling and serves as a therapeutic target for antiviral therapy

  2025cited by this paper
• Empagliflozin attenuates pyroptosis by regulating thioredoxin-NLRP3 inflammasome axis in a high fat cholesterol diet/streptozotocin model of atherosclerosis.

  2025cited by this paper
• Deep learning-based dipeptidyl peptidase IV inhibitor screening, experimental validation, and GaMD/LiGaMD analysis

  2025cited by this paper
• Dissecting ncRNA pathways and omics integration.

  2025cited by this paper
• Metabolomics-Driven Standardization of Herbal Medicine: Advances, Applications, and Sustainability Considerations

  2025cited by this paper
• Honey and lime juice flavonoids as potential adjunctive remedies against obesity and diabetes mellitus risks via glucagon receptor and glucagon-like peptide-1 receptor binding mechanisms: an in-silico investigation

  2025influential reference
• Hidden Hunger: A Forgotten Comorbidity of Metabolic‐Syndrome‐Associated Fatty Liver Disease

  2025cited by this paper
• Cardiovascular implications of metabolic dysfunction-associated fatty liver disease and type 2 diabetes mellitus: A meta-analysis

  2025cited by this paper
• Quercetin Enhances GLP‐1 Secretion via TAS2R38‐Mediated PLC Signaling in Enteroendocrine L‐Cells

  2025influential reference
• Biological activity of secondary metabolites of actinomycetes and their potential sources as antineoplastic drugs: a review

  2025cited by this paper
• Genome editing of TXNIP in human pluripotent stem cells for the generation of hepatocyte-like cells and insulin-producing islet-like aggregates

  2025cited by this paper
• Structural pharmacology and mechanisms of GLP-1R signaling.

  2025cited by this paper
• Flavonoids regulating NLRP3 inflammasome: a promising approach in alleviating diabetic peripheral neuropathy

  2025cited by this paper
• Barriers and Strategies for Oral Peptide and Protein Therapeutics Delivery: Update on Clinical Advances

  2025cited by this paper
• Unlocking the multifaceted roles of GLP-1: Physiological functions and therapeutic potential

  2025cited by this paper
• Flavonoids for gastrointestinal tract local and associated systemic effects: A review of clinical trials and future perspectives

  2025cited by this paper
• Enhancing β-cell function and identity in type 2 diabetes: The protective role of Coptis deltoidea C. Y. Cheng et Hsiao via glucose metabolism modulation and AMPK signaling activation.

  2024cited by this paper
• Discovery of Non-Peptide GLP-1 Positive Allosteric Modulators from Natural Products: Virtual Screening, Molecular Dynamics, ADMET Profiling, Repurposing, and Chemical Scaffolds Identification

  2024cited by this paper
• Novel Therapeutic Approach for Obesity: Seaweeds as an Alternative Medicine with the Latest Conventional Therapy

  2024cited by this paper
• Glucagon-like peptide-1 receptor: mechanisms and advances in therapy

  2024cited by this paper
• The interplay between gut microbiota, short-chain fatty acids, and implications for host health and disease

  2024cited by this paper
• Ferulic acid restores mitochondrial dynamics and autophagy via AMPK signaling pathway in a palmitate-induced hepatocyte model of metabolic syndrome

  2024cited by this paper
• The Discovery and Characterization of a Potent DPP-IV Inhibitory Peptide from Oysters for the Treatment of Type 2 Diabetes Based on Computational and Experimental Studies

  2024cited by this paper
• Omarigliptin/rosinidin combination ameliorates cyclophosphamide-induced lung toxicity in rats: The interaction between glucagon-like peptide-1, TXNIP/NLRP3 inflammasome signaling, and PI3K/Akt/FoxO1 axis.

  2024cited by this paper
• Ginseng extract improves pancreatic islet injury and promotes β-cell regeneration in T2DM mice

  2024cited by this paper
• mTORC1 regulates cell survival under glucose starvation through 4EBP1/2-mediated translational reprogramming of fatty acid metabolism

  2024cited by this paper
• Resmetirom, the first approved drug for the management of metabolic dysfunction-associated steatohepatitis: Trials, opportunities, and challenges.

  2024cited by this paper
• FoxO6-Mediated TXNIP Induces Lipid Accumulation in the Liver through NLRP3 Inflammasome Activation

  2024cited by this paper
• Piquing artificial intelligence towards drug discovery: Tools, techniques, and applications

  2024cited by this paper
• Pharmacological Inhibition of the NLRP3 Inflammasome: Structure, Molecular Activation, and Inhibitor-NLRP3 Interaction

  2023cited by this paper
• Berberine-induced glucagon-like peptide-1 and its mechanism for controlling type 2 diabetes mellitus: a comprehensive pathway review

  2023cited by this paper
• Thioredoxin/Glutaredoxin Systems and Gut Microbiota in NAFLD: Interplay, Mechanism, and Therapeutical Potential

  2023cited by this paper
• Molecular docking as a tool for the discovery of molecular targets of nutraceuticals in diseases management

  2023cited by this paper
• Therapeutic strategies targeting AMPK-dependent autophagy in cancer cells.

  2023cited by this paper
• Hyperglycemia and Oxidative Stress: An Integral, Updated and Critical Overview of Their Metabolic Interconnections

  2023cited by this paper
• Short-Chain Fatty-Acid-Producing Bacteria: Key Components of the Human Gut Microbiota

  2023cited by this paper
• Role of Fenugreek, Cinnamon, Curcuma longa, Berberine and Momordica charantia in Type 2 Diabetes Mellitus Treatment: A Review

  2023cited by this paper
• An Update on the Anti-diabetic Functions of Genistein: A Soybean (Glycine max (L.) Merr.) Isoflavone

  2023cited by this paper
• Systematic investigation of the underlying mechanisms of GLP-1 receptor agonists to prevent myocardial infarction in patients with type 2 diabetes mellitus using network pharmacology

  2023cited by this paper
• Clinical Implications of Herbal Supplements in Conventional Medical Practice: A US Perspective

  2022cited by this paper
• Novel Strategies for the Bioavailability Augmentation and Efficacy Improvement of Natural Products in Oral Cancer

  2022cited by this paper
• A review on phytochemical and pharmacological facets of tropical ethnomedicinal plants as reformed DPP-IV inhibitors to regulate incretin activity

  2022cited by this paper
• In vitro evaluation of 2-pyrazoline derivatives as DPP-4 inhibitors

  2022cited by this paper
• Strategies for Improving Bioavailability, Bioactivity, and Physical-Chemical Behavior of Curcumin

  2022cited by this paper
• Bioavailability Enhancement Techniques for Poorly Aqueous Soluble Drugs and Therapeutics

  2022cited by this paper
• Non-alcoholic fatty liver disease, metabolic syndrome, and type 2 diabetes mellitus: where do we stand today?

  2022cited by this paper
• Physiological and Pathophysiological Roles of Thioredoxin Interacting Protein: A Perspective on Redox Inflammation and Metabolism

  2022cited by this paper
• Improvement of Glucose Tolerance by Food Factors Having Glucagon-Like Peptide-1 Releasing Activity

  2021cited by this paper
• Multi-Target Approaches in Metabolic Syndrome

  2021cited by this paper
• Whole Alga, Algal Extracts, and Compounds as Ingredients of Functional Foods: Composition and Action Mechanism Relationships in the Prevention and Treatment of Type-2 Diabetes Mellitus

  2021cited by this paper
• Challenges of peptide and protein drug delivery by oral route: Current strategies to improve the bioavailability

  2021cited by this paper
• Prospect into therapeutic potentials of Moringa oleifera phytocompounds against cancer upsurge: de novo synthesis of test compounds, molecular docking, and ADMET studies

  2021cited by this paper
• Role of moesin in the effect of glucagon-like peptide-1 on advanced glycation end products-induced endothelial barrier dysfunction.

  2021cited by this paper
• GLP-1 mimetics as a potential therapy for nonalcoholic steatohepatitis

  2021cited by this paper
• Bioprospecting Sponge-Associated Marine Cyanobacteria to Produce Bioactive Compounds

  2020cited by this paper
• Role of ASM/Cer/TXNIP signaling module in the NLRP3 inflammasome activation

  2020cited by this paper
• Effects of Momordica charantia (Bittergourd) and Trigonella foenum-graecum (Fenugreek) Supplements in Type-2 Diabetics Taking Allopathic Drugs

  2020cited by this paper
• Chronic Inflammation in Non-Alcoholic Steatohepatitis: Molecular Mechanisms and Therapeutic Strategies

  2020cited by this paper
• Probiotics supplementation and insulin resistance: a systematic review

  2020cited by this paper
• GLP-1 receptor agonists in the treatment of type 2 diabetes – state-of-the-art

  2020cited by this paper
• Effects of brown seaweeds on postprandial glucose, insulin and appetite in humans - A randomized, 3-way, blinded, cross-over meal study.

  2020cited by this paper
• The Effects of Hydro-Alcoholic Extract of Fenugreek Seeds on the Lipid Profile and Oxidative Stress in Fructose-Fed Rats

  2020cited by this paper
• In vitro modulation of glucagon-like peptide release by DPP-IV inhibitory polyphenol-polysaccharide conjugates of sprouted quinoa yoghurt.

  2020cited by this paper
• "Natural" is not synonymous with "Safe": Toxicity of Natural Products Alone and in combination with pharmaceutical agents.

  2020cited by this paper
• Seaweed-derived bioactives as potential energy regulators in obesity and type 2 diabetes.

  2020cited by this paper
• Screening GLP-1 Receptor Ligands from Natural Products in Herbs through High-Content Technique.

  2019cited by this paper
• Review of Ginseng Anti-Diabetic Studies

  2019cited by this paper
• Natural phenolic compounds potentiate hypoglycemia via inhibition of Dipeptidyl peptidase IV

  2019cited by this paper
• Glucagon-like peptide 1 (GLP-1)

  2019cited by this paper
• GLP-1 Receptor Activation Abrogates β-Cell Dysfunction by PKA Cα-Mediated Degradation of Thioredoxin Interacting Protein

  2019cited by this paper
• Pharmacologic Application Potentials of Sulfated Polysaccharide from Marine Algae

  2019cited by this paper
• Disruptive Technology: CRISPR/Cas-Based Tools and Approaches

  2019cited by this paper
• Genistein enhances the secretion of glucagon-like peptide-1 (GLP-1) via downregulation of inflammatory responses.

  2019cited by this paper
• New Drugs from the Sea: Pro-Apoptotic Activity of Sponges and Algae Derived Compounds

  2019cited by this paper
• Restoration of GLP-1 secretion by Berberine is associated with protection of colon enterocytes from mitochondrial overheating in diet-induced obese mice

  2018cited by this paper
• TXNIP regulates AKT‐mediated cellular senescence by direct interaction under glucose‐mediated metabolic stress

  2018cited by this paper
• Nutraceuticals: opening the debate for a regulatory framework

  2018cited by this paper
• Role of oxidative stress, infection and inflammation in male infertility

  2018cited by this paper
• Effects of Glucagon-Like Peptide-1 on Oxidative Stress and Nrf2 Signaling

  2017cited by this paper
• Antidiabetic and anti-inflammatory potential of sulphated polygalactans from red seaweeds Kappaphycus alvarezii and Gracilaria opuntia

  2017cited by this paper
• TXNIP in Metabolic Regulation: Physiological Role and Therapeutic Outlook

  2017cited by this paper
• Glucagon-like peptide-1 improves beta-cell antioxidant capacity via extracellular regulated kinases pathway and Nrf2 translocation.

  2016cited by this paper
• Cytokines Regulate β-Cell Thioredoxin-interacting Protein (TXNIP) via Distinct Mechanisms and Pathways*

  2016cited by this paper
• Berberine induces GLP-1 secretion through activation of bitter taste receptor pathways.

  2015cited by this paper
• Glucagon-like Peptide-1 (GLP-1) Analogs: Recent Advances, New Possibilities, and Therapeutic Implications

  2014cited by this paper
• Minireview: Thioredoxin-interacting protein: regulation and function in the pancreatic β-cell.

  2014cited by this paper
• GLP-1 receptor agonists vs. DPP-4 inhibitors for type 2 diabetes: is one approach more successful or preferable than the other?

  2014cited by this paper
• The thioredoxin antioxidant system.

  2014cited by this paper
• Sulfated‐polysaccharide fraction extracted from red algae Gracilaria birdiae ameliorates trinitrobenzenesulfonic acid‐induced colitis in rats

  2014cited by this paper
• The role of short-chain fatty acids in the interplay between diet, gut microbiota, and host energy metabolism

  2013cited by this paper
• Short-Chain Fatty Acids Stimulate Glucagon-Like Peptide-1 Secretion via the G-Protein–Coupled Receptor FFAR2

  2012cited by this paper
• A Sulfated-Polysaccharide Fraction from Seaweed Gracilaria birdiae Prevents Naproxen-Induced Gastrointestinal Damage in Rats

  2012cited by this paper
• Berberine Improves Glucose Metabolism in Diabetic Rats by Inhibition of Hepatic Gluconeogenesis

  2011cited by this paper
• TCM Database@Taiwan: The World's Largest Traditional Chinese Medicine Database for Drug Screening In Silico

  2011cited by this paper
• Anti-obesity and anti-diabetic effects of fucoxanthin on diet-induced obesity conditions in a murine model.

  2009cited by this paper
• Mechanism of action of inhibitors of dipeptidyl-peptidase-4 (DPP-4).

  2009cited by this paper
• Emerging role of dipeptidyl peptidase-4 inhibitors in the management of type 2 diabetes

  2008cited by this paper
• [Glucagon-like peptide-1(GLP-1)].

  2004cited by this paper
• Glucagon-like peptide 1 inhibits cell apoptosis and improves glucose responsiveness of freshly isolated human islets.

  2003cited by this paper

• Computational and Experimental Evaluation of Alkaloid Compounds from Papaver somniferum as Dual COX-2 and TNF-α Inhibitors

  2026cites this paper